Anemia is defined as a state in which decreased erythrocyte count and low hemoglobin level are found. Heme of hemoglobin is a complex of protoporphyrin and iron. Heme is also the constituent of various respiratory enzymes such as cytochromes, catalase and peroxidase.
The types and structures of porphyrins were clarified by Fischer and Orth (1937) . Sehemin and Rittenberg (1946) found that [15N] glycine was incorporated into heme of hemoglobin of rat erythrocytes. Since then, the study of heme synthesis has made a rapid progress owing to the investigations by Sano and Rimington (1963) , Gibson et al. (1955) , Granick and Mauzerall (1958a, b) and others. The synthetic pathway of heme has been shown to consist of three stages as shown in Fig. 1 . In the first stage, S-aminolevulinic acid (ALA) synthetase, which is a mitochondrial enzyme, catalyzes the condensation of glycine and succinyl Co-A with the aid of a coenzyme pyridoxal phosphate. In the second stage, corproporphyrinogen (CPG) is synthesized through porphobilinogen (PBG) and uroporphyrinogen (UPG). In the third stage, iron is introduced into protoporphyrin to form heme by a mitochondrial enzyme. Heikel et al. (1958) claimed that the last stage is not enzymatic. But this reaction is now believed to be enzymatic based on the experiment of Labbe and Hubbard (1960) in which rat liver mito chondria were used as an enzyme source, and from the works by Goldberg (1959) , Kagawa et al. (1959) and Yoneyama et al. (1962) who studied the heat stability, pH-dependency, and substrate specificity of the reaction with chick and duck nu cleated erythroblasts. This enzyme is called heme synthetase or protoporphyrin ferrochelatase. As Heilmeyer and Clotten (1966) pointed out, interruption of part of the synthetic pathway of porphyrin and heme would naturally cause anemia and other clinical symptoms. As for plumbism and sideroachrestic anemia , there are detailed reports on changes in the first and second stages in Fig. 1 . Disturbance of heme synthetase (the third stage) has not been evidently demonstrated , and only a few clinical reports (Lochhead and Goldberg 1961; Bottomley 1968) have recently appeared. This is because the estimation of the dynamic state of porphyrins in the human body requires the measurement of free porphyrins at present , and because only peripheral blood and urine are available as test materials . For more direct assessment to the dynamic state of porphyrin , we attempted to measure the heme synthetase activity of the human bone marrow cells and tried to expore the role of this enzyme in various anemia. Studies on changes of this activity may be important in understanding the mechanisms of various anemias . Iron deficiency anemia Hepatic diseases Table 7 shows the results of 1 case of liver cirrhosis, 3 cases of acute hepatitis and 1 case of portal hypertension with liver cirrhosis. There was no significant difference in the enzyme level between these diseases and the control (p, >0.05). Table 8 shows the results of 2 cases of uremia and 6 cases of chronic nephritis without uremia. No significant difference in the level of enzyme was seen Other diseases induced must be different from that in aplastic anemia. In the cases of acute and chronic hepatitis and liver cirrhosis, there is an increase of erythrocyte protoporphyrin, which becomes normal upon the clinical treatment. The increase of porphyrin is believed to be due to the secondary disturbance of heme synthesis in the bone marrow induced by the hepatic disorders. With respect to the activity of heme synthetase, however, we found no significant difference between hepatic diseases and the control (p, >0.05). In the cases of liver cirrhosis, the enzyme level was one fourth that of the control though anemia was slight. In these cases subsequent development of anemia may be predicted. The size of heme pool and its utilization should also be considered in the develop ment of anemia.
MATERIALS AND METHODS

Renal diseases
There have been many reports concerning abnormal metabolism of porphyrin and anemia in cancer. Greenstein and Andervort (1942) reported that the decreas ed catalase activity was characteristic of the tumor bearing animal . Since then, the lowered activities of various heme-containing respiratory enzymes other than catalase, such as tryptophan pyrolase and cytochromes , have been reported (Miura and Kuru 1965) . Nakahara and Fukuoka (1949) clarified the biological function of toxohormone in connection with porphyrin metabolism . Ono et al. (1959) found that the increased level of free porphyries in the liver of a tumor-bearing or toxohormone-administered rat became completely normal after administration of FeCl3 and that, at the same time, anemia and the decreased liver catalase level were improved to a certain degree. On the other hand , Origieness et al. (1961) inferred that in Ehrlich's ascites tumor and the mouse liver , incorporation of 59Fe into heme was lower when ALA was used as substrate than when protoporphyrin was used. Some claim that the action of ALA dehydrase is inhibited (Tschudy and Collins 1957). Significant difference in the level of heme synthetase was found between the patients with cachexia and those without cachexia in cancer patients . The patients without cachexia showed a high level of heme synthetase , next to that of iron deficiency anemia. Generally, the amount of iron in plasma-pool and labile pool is decreased even in the early stage of cancer, for iron is trapped in the reticuloendothelial system. This latent state of iron deficiency may be responsible for the high level of heme synthetase . In the advanced stage of cancer the reticuloendothelial function is lowered , and iron is incorporated into the tumor . Therefore, deterioration of tissue is accelerated owing partly to cancer anemia , and cachexia develops. Home symthetase activity may be lowered by disturbance of tissue respiration.
In summary of our results, the changes of heme synthetase activity may be classified into the following 3 groups (Table 11) . (1) The cases of anemia in which the enzyme activity is normal or higher than the control: the patients with anemia due to iron deficiency and those with cancer without cachexia . (2) The cases of slight anemia in which the enzyme activity is abnormally low: the patients with hyperthyroidism and some of those with hepatic diseases . (3) The cases of marked anemia in which the enzyme activity is low: the patients with cancer with cachexia 
